Genetic Risk Profiling in Metastatic Prostate Carcinoma

转移性前列腺癌的遗传风险分析

基本信息

  • 批准号:
    6722907
  • 负责人:
  • 金额:
    $ 15.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-03-18 至 2006-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): PSA screening has contributed to a dramatic increase in the number of prostate cancer cases diagnosed and a subtle decrease in mortality from this disease. Unfortunately, many patients still present with aggressive, potentially lethal disease either because 1) the patient did not participate in a screening program, 2) the program did not identify the disease early enough for cure or 3) the treatment chosen did not eradicate the disease. At the same time, many men go through years of unnecessary screening and/or are diagnosed with prostate carcinoma with low metastatic potential. What is needed are markers to identify men, not at high risk of having prostate carcinoma, but at high risk of dying of prostate carcinoma. Identification of high risk men prior to developing the disease would allow intense screening and/or prophylaxis while sparing those at low risk years of screening. Identification of high risk men after diagnoses would allow targeted therapy while sparing those at low risk potentially morbid treatment. We believe that analysis of common polymorphic variants will allow exactly this risk stratification. The objective of this application is to identify which DNA polymorphisms that are associated with risk for metastatic prostate carcinoma and therefore are potential markers for aggressive prostate cancer. We propose to perform a case-control study to identify polymorphic variants associated with advanced prostate cancer using patients with metastatic prostate carcinoma as our cases and individuals with little or no risk of ever developing prostate carcinoma as our controls. There are two specific aims to this proposal. (I) To establish a bank of somatic DNAs from advanced prostate cancer patients and race matched controls. (II)To search for associations between genotypes and risk of advanced prostate carcinoma. The rationale for studying patients with metastatic disease is two fold. First, patients with metastatic disease unequivocally have clinically important prostate carcinoma. As a result, there are no patients with indolent disease to obscure significant associations. Second, since these are the patients in whom earlier identification has the potential to make the greatest impact, they are the patients who should be studied. At the conclusion of this study, we will have a panel of markers with the potential to predict, in future prospective studies, which patients are at high risk of eventual death from prostate carcinoma.
描述(由申请人提供):PSA筛查有助于前列腺癌诊断病例数量的急剧增加和这种疾病死亡率的微妙下降。不幸的是,许多患者仍然患有侵袭性的、潜在致命的疾病,这是因为1)患者没有参加筛查计划,2)该计划没有足够早地发现疾病以治愈或3)所选择的治疗没有根除疾病。与此同时,许多男性经历了多年不必要的筛查和/或被诊断患有低转移潜力的前列腺癌。我们需要的是识别男性的标志物,这些男性不是处于患前列腺癌的高风险中,而是处于死于前列腺癌的高风险中。在发生疾病之前识别高风险男性将允许密集的筛查和/或预防,同时保留那些处于低风险年的筛查。在诊断后识别高风险男性将允许靶向治疗,同时保留那些低风险的潜在病态治疗。我们相信,分析常见的多态性变异将允许这种风险分层。本申请的目的是鉴定哪些DNA多态性与转移性前列腺癌的风险相关,因此是侵袭性前列腺癌的潜在标志物。我们建议进行一项病例对照研究,以确定与晚期前列腺癌相关的多态性变异,使用转移性前列腺癌患者作为我们的病例,很少或没有发生前列腺癌风险的个体作为我们的对照。这项建议有两个具体目标。(I)目的建立晚期前列腺癌患者和正常人的体细胞DNA库。(II)探讨基因型与晚期前列腺癌的关系。研究转移性疾病患者的基本原理有两个方面。首先,转移性疾病患者明确具有临床重要的前列腺癌。因此,没有患者的惰性疾病,以掩盖显着的关联。第二,由于这些患者的早期识别有可能产生最大的影响,他们是应该进行研究的患者。在这项研究结束时,我们将有一组标志物,在未来的前瞻性研究中,这些标志物有可能预测哪些患者最终死于前列腺癌的高风险。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma.
  • DOI:
    10.1002/pros.21098
  • 发表时间:
    2010-05-01
  • 期刊:
  • 影响因子:
    2.8
  • 作者:
    Lubahn, Jessica;Berndt, Sonja I.;Jin, Carol H.;Klim, Aleksandra;Luly, Jason;Wu, William S.;Isaacs, Sarah;Wiley, Kathleen;Isaacs, William B.;Suarez, Brian K.;Hayes, Richard B.;Kibel, Adam S.
  • 通讯作者:
    Kibel, Adam S.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADAM S KIBEL其他文献

ADAM S KIBEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADAM S KIBEL', 18)}}的其他基金

Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancer
多基因风险分层结合 mpMRI 来识别临床相关的前列腺癌
  • 批准号:
    10610626
  • 财政年份:
    2023
  • 资助金额:
    $ 15.3万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7051995
  • 财政年份:
    2005
  • 资助金额:
    $ 15.3万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    6859610
  • 财政年份:
    2005
  • 资助金额:
    $ 15.3万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7560021
  • 财政年份:
    2005
  • 资助金额:
    $ 15.3万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7198099
  • 财政年份:
    2005
  • 资助金额:
    $ 15.3万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7344737
  • 财政年份:
    2005
  • 资助金额:
    $ 15.3万
  • 项目类别:
Genetic Risk Profiling in Metastatic Prostate Carcinoma
转移性前列腺癌的遗传风险分析
  • 批准号:
    6556523
  • 财政年份:
    2003
  • 资助金额:
    $ 15.3万
  • 项目类别:
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE
12P 前列腺肿瘤抑制基因的鉴定
  • 批准号:
    6232986
  • 财政年份:
    2001
  • 资助金额:
    $ 15.3万
  • 项目类别:
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE
12P 前列腺肿瘤抑制基因的鉴定
  • 批准号:
    6514864
  • 财政年份:
    2001
  • 资助金额:
    $ 15.3万
  • 项目类别:
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE
12P 前列腺肿瘤抑制基因的鉴定
  • 批准号:
    6633919
  • 财政年份:
    2001
  • 资助金额:
    $ 15.3万
  • 项目类别:

相似海外基金

Deep Learning Image Analysis Algorithms to Improve Oral Cancer Risk Assessment for Oral Potentially Malignant Disorders
深度学习图像分析算法可改善口腔潜在恶性疾病的口腔癌风险评估
  • 批准号:
    10805177
  • 财政年份:
    2023
  • 资助金额:
    $ 15.3万
  • 项目类别:
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
高风险良性乳腺诊断女性的临床乳腺癌风险预测模型
  • 批准号:
    10719777
  • 财政年份:
    2023
  • 资助金额:
    $ 15.3万
  • 项目类别:
Mechanisms of tamoxifen-associated endometrial cancer risk
他莫昔芬相关子宫内膜癌风险的机制
  • 批准号:
    10650054
  • 财政年份:
    2023
  • 资助金额:
    $ 15.3万
  • 项目类别:
Optimization of a personalized skin cancer risk intervention for at-risk young adults
针对高危年轻人的个性化皮肤癌风险干预措施的优化
  • 批准号:
    10582944
  • 财政年份:
    2023
  • 资助金额:
    $ 15.3万
  • 项目类别:
Ovarian cancer risk stratification using circulating miRNAs to assess BRCAness
使用循环 miRNA 评估 BRCA 的卵巢癌风险分层
  • 批准号:
    10724815
  • 财政年份:
    2023
  • 资助金额:
    $ 15.3万
  • 项目类别:
Understanding the impact of an EHR-integrated hereditary cancer risk assessment application on patient-provider communication
了解 EHR 集成遗传性癌症风险评估应用程序对患者与提供者沟通的影响
  • 批准号:
    10831167
  • 财政年份:
    2023
  • 资助金额:
    $ 15.3万
  • 项目类别:
Oral Dysplasia and Oral Cavity Cancer Risk in Dental and Medical Surveillance Settings Using a Chairside Chip-Based Cytopathology Tool
使用基于椅旁芯片的细胞病理学工具评估牙科和医疗监测环境中的口腔发育不良和口腔癌风险
  • 批准号:
    10344966
  • 财政年份:
    2022
  • 资助金额:
    $ 15.3万
  • 项目类别:
Type II diabetes, related biomarkers and medications, and ovarian cancer risk
II 型糖尿病、相关生物标志物和药物以及卵巢癌风险
  • 批准号:
    10601473
  • 财政年份:
    2022
  • 资助金额:
    $ 15.3万
  • 项目类别:
Advancing Evidence of the Associations between specific Benign Breast Diagnoses and Future Breast Cancer Risk
推进特定良性乳腺诊断与未来乳腺癌风险之间关联的证据
  • 批准号:
    10654561
  • 财政年份:
    2022
  • 资助金额:
    $ 15.3万
  • 项目类别:
Type II diabetes, related biomarkers and medications, and ovarian cancer risk
II 型糖尿病、相关生物标志物和药物以及卵巢癌风险
  • 批准号:
    10551238
  • 财政年份:
    2022
  • 资助金额:
    $ 15.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了